Press release
Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation.It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Factor Receptor Family (EFGR) are present on the cell surface and anomalies like mutations leads to the cancer formation and its members have been found to have activity like receptor tyrosine kinases. EFGR Members of these families have been found to be overexpressed in various malignancies like breast cancer, glioblastoma and lung cancer. They are utilized for formulating targeted therapeutics for cancer treatment. Her1/ Her2 are commonly found to be overexpressed in case of breast cancer and many cancer therapeutics have been developed to treat metastatic condition.Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years.
Download Report:
https://www.kuickresearch.com/report-Tyrosine-Kinase-Inhibitors-Market-&-Pipeline-Insight-2015.php
Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role.
Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech’s trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EFGR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories.
Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.
" Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015" Report Highlight:
* Global Tyrosine Kinase Therapeutics Market Overview
* Mechanism of Tyrosine Kinase Therapeutics
* Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
* Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs
* Majority Drugs in Preclinical Phase: 239 Drugs
* Marketed Tyrosine Kinase Inhibitors: 58 Drugs
* Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication
For Report Sample Contact: neeraj@kuickresearch.com or
visit: https://www.kuickresearch.com
Recent Publications:
* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015 here
News-ID: 601130 • Views: …
More Releases from Kuick Resarch

Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…

Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…

Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…

Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
More Releases for Tyrosine
Global Tyrosine Supplements Market: A Comprehensive Overview
The global tyrosine supplements market was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9% from 2024 to 2030.
Global Tyrosine Supplements Market Overview
The global tyrosine supplements market is experiencing significant growth, driven by increasing consumer awareness of its cognitive and mood-enhancing benefits. Tyrosine, an amino acid, is widely…
Bruton Tyrosine Kinase (BTK) Inhibitors Market
Introduction
Bruton Tyrosine Kinase (BTK) inhibitors represent a critical class of medications in the treatment of various cancers, primarily blood-related malignancies. BTK is an enzyme crucial in the B-cell receptor signaling pathway, essential for B-cell development and function. This signaling pathway plays a central role in many types of blood cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, these drugs effectively prevent the proliferation…
Global Tyrosine Market 2015-2025 | Growing Opportunities and Trends in Tyrosine …
The Market Research Store has added the latest report on the Global Tyrosine Market which includes the historical data from 2015 to 2019 and has also precisely forecasted data from 2020 to 2025. The global Tyrosine market anticipates to showcase market value in terms of USD Million during the forecast period 2020 to 2025. According the research analyst the market will witness a steady growth during the coming years.
Get Sample…
Tyrosine Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Tyrosine Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/global-tyrosine-market_p130094.html
Scope of the Report:
The worldwide market for Tyrosine is…
Glycyl Tyrosine Market SWOT Analysis 2018-2023
Future Market Reports on Global Glycyl Tyrosine 2018 Research Report presents a professional and complete analysis of Global Glycyl Tyrosine Market on the current market situation. The Global Glycyl Tyrosine Market 2018 report includes Glycyl Tyrosine market Revenue, market Share, Glycyl Tyrosine industry volume, market Trends, Growth aspects. It analyses the important factors of the Glycyl Tyrosine market based on present industry situations, Glycyl Tyrosine market demands, business strategies utilized…
Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors
2. Tyrosine Kinase: An Overview
3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies
4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3…